Lead · News
Ozempic face is pulling Gen X to surgery a decade early
GLP-1 facial hollowing is moving a high-spend injectable cohort toward permanent surgery.
On June 24, 2026, Fortune reported that ASPS president Dr. Bob Basu now routinely sees facelift patients in their 40s and 50s, a group that used to be a "60-plus crowd." The driver he names is GLP-1 weight loss, which leaves facial hollowing and sagging that injectables can soften but not permanently correct. For a clinic, that is the whole story in one sentence: a problem you have been treating with filler is starting to read, to some patients, as a surgical problem.
